AU2010321787B2 - Biomarkers of cancer - Google Patents

Biomarkers of cancer Download PDF

Info

Publication number
AU2010321787B2
AU2010321787B2 AU2010321787A AU2010321787A AU2010321787B2 AU 2010321787 B2 AU2010321787 B2 AU 2010321787B2 AU 2010321787 A AU2010321787 A AU 2010321787A AU 2010321787 A AU2010321787 A AU 2010321787A AU 2010321787 B2 AU2010321787 B2 AU 2010321787B2
Authority
AU
Australia
Prior art keywords
subject
stage
antigens
ovarian cancer
ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010321787A
Other languages
English (en)
Other versions
AU2010321787A1 (en
Inventor
Cicek Gercel-Taylor
Douglas D. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of AU2010321787A1 publication Critical patent/AU2010321787A1/en
Application granted granted Critical
Publication of AU2010321787B2 publication Critical patent/AU2010321787B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010321787A 2009-11-20 2010-11-19 Biomarkers of cancer Ceased AU2010321787B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26323509P 2009-11-20 2009-11-20
US61/263,235 2009-11-20
PCT/US2010/057427 WO2011063232A1 (en) 2009-11-20 2010-11-19 Biomarkers of cancer

Publications (2)

Publication Number Publication Date
AU2010321787A1 AU2010321787A1 (en) 2012-06-14
AU2010321787B2 true AU2010321787B2 (en) 2015-06-11

Family

ID=44060024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010321787A Ceased AU2010321787B2 (en) 2009-11-20 2010-11-19 Biomarkers of cancer

Country Status (6)

Country Link
US (1) US20150005187A1 (cg-RX-API-DMAC7.html)
EP (1) EP2501845A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013511728A (cg-RX-API-DMAC7.html)
AU (1) AU2010321787B2 (cg-RX-API-DMAC7.html)
CA (1) CA2781408A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011063232A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102393458B (zh) * 2011-08-24 2013-12-18 绍兴市人民医院 一种早期乳腺癌血清诊断试剂
US20140186293A1 (en) * 2012-12-31 2014-07-03 University Of Louisville Research Foundation, Inc. Immunoglobulin-bound extracellular vesicles and uses thereof
CA2894538A1 (en) * 2013-01-31 2014-08-07 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ari Autoantibody signature for the early detection of ovarian cancer
EP3281016A1 (en) * 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
KR20230079198A (ko) * 2020-10-05 2023-06-05 프리놈 홀딩스, 인크. 결장 세포 증식성 장애의 조기 검출을 위한 마커

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US20050158737A1 (en) * 2002-03-27 2005-07-21 Alison Banham Tumour associated antigens
US20070167405A1 (en) * 2001-09-28 2007-07-19 Huflejt Margaret E Galectins -1 and -4 in tumor development

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780161B1 (fr) 1998-06-17 2000-09-29 Centre Nat Rech Scient Procede de diagnostic precoce du cancer base sur la recherche d'auto-anticorps diriges contre la proteine csk et trousse pour sa mise en oeuvre
GB0412301D0 (en) * 2004-06-02 2004-07-07 Diagenic As Product and method
JP2007322211A (ja) * 2006-05-31 2007-12-13 Green Peptide Co Ltd がん患者の予後予測方法
CN101657719A (zh) * 2007-01-26 2010-02-24 路易斯维尔大学研究基金会公司 检测用于诊断和表征障碍的自身抗体的方法
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20070167405A1 (en) * 2001-09-28 2007-07-19 Huflejt Margaret E Galectins -1 and -4 in tumor development
US20050158737A1 (en) * 2002-03-27 2005-07-21 Alison Banham Tumour associated antigens

Also Published As

Publication number Publication date
EP2501845A4 (en) 2013-04-24
EP2501845A1 (en) 2012-09-26
CA2781408A1 (en) 2011-05-26
US20150005187A1 (en) 2015-01-01
JP2013511728A (ja) 2013-04-04
WO2011063232A1 (en) 2011-05-26
AU2010321787A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
Caron et al. Cancer immunomics using autoantibody signatures for biomarker discovery
González-Buitrago et al. Urinary proteomics
US7112408B2 (en) Detection of ovarian cancer based upon alpha-haptoglobin levels
US8679769B2 (en) Detection of endometrial secretion markers for assessment of endometriosis
Yang et al. Identification of candidate biomarkers for the early detection of nasopharyngeal carcinoma by quantitative proteomic analysis
US20150005187A1 (en) Biomarkers of Cancer
EP1775590A1 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
Ura et al. A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate
AU2023210591B2 (en) Markers of endometrial cancer
Periyasamy et al. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer
US20140066325A1 (en) Protein Biomarkers for the Diagnosis of Prostate Cancer
US8642347B2 (en) Urinary CA125 peptides as biomarkers of ovarian cancer
Giri et al. Targeted proteomics using parallel reaction monitoring confirms salivary proteins indicative of metastatic triple-negative breast cancer
Ravipaty et al. Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis of prostate cancer
KR20230165283A (ko) 암을 위한 바이오마커 및 요법 표적으로서의 시트룰린화된 단백질
US20120277326A1 (en) Biomarkers of cancer
Streckfus et al. A comparison of the proteomic expression in pooled saliva specimens from individuals diagnosed with ductal carcinoma of the breast with and without lymph node involvement
Taylor et al. Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components
EP2115473B1 (en) Markers for transformed epithelium and potential targets for therapy of cancer of the gingivo buccal complex
WO2013166343A2 (en) Mrm-ms signature assay
WO2013109598A1 (en) Materials and methods for detecting and/or predicting necrotizing enterocolitis in infants
Juanes-Velasco et al. Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid. Cancers 2022, 14, 449
Baldetorp et al. Analysis of protein expression in pure cell nuclei populations isolated from human breast cancer tissue by DNA flow cytometric sorting
CN121410263A (zh) 胆道癌免疫治疗相关的尿液蛋白标志物及其应用
GB2541712A (en) Autoantibody biomarkers for gastric cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired